首頁 > 市場調查報告書 > 製藥

自體免疫疾病

市場調查報告書

商品編碼

1406809

纖維肌痛治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、配銷通路、地區和競爭細分

Fibromyalgia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, by Distribution Channel, by region, and Competition

出版日期: 2023年11月07日 | 出版商:

TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2022 年，全球纖維肌痛治療市場價值為 29.8 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年CAGR為3.90%。纖維肌痛治療是一種旨在控制症狀和改善生活品質的綜合方法對於患有纖維肌痛的人來說，纖維肌痛是一種慢性疼痛疾病，其特徵是廣泛的肌肉骨骼疼痛、疲勞、睡眠障礙，通常還有心理症狀。纖維肌痛的治療通常涉及根據患者個體的需求和偏好量身定做的醫學、心理和生活方式策略的結合。物理治療師制定量身定做的運動計劃，重點是提高靈活性、力量和整體身體功能。通常建議進行溫和、低衝擊力的運動，例如游泳、散步或太極拳。定期與醫療保健提供者進行追蹤對於評估治療效果並對藥物或其他療法進行必要的調整至關重要。監測潛在副作用並及時解決它們是藥物管理的一部分。

全球纖維肌痛盛行率的不斷上升，特別是在已開發國家，一直是市場的重要驅動力。越來越多的人被診斷出患有纖維肌痛，需要治療的患者人數也越來越多。對纖維肌痛根本原因的持續研究和新治療方式的開發擴大了可用療法的範圍並推動了市場成長。製藥公司一直在積極投資開發專門針對纖維肌痛症狀的藥物，包括疼痛、睡眠障礙和情緒障礙。纖維肌痛治療的多模式方法的趨勢，結合藥物、物理治療、心理介入和生活方式的改變，增加了對各種治療方案的需求。政府旨在改善慢性疼痛（包括纖維肌痛）管理的醫療保健措施和政策提振了市場。隨著全球人口持續老化，纖維肌痛等慢性疼痛疾病的盛行率預計將上升，進一步增加對治療的需求。向以患者為中心的護理的轉變，即根據個人需求和偏好客製化治療計劃，增加了對各種治療選擇的需求。

主要市場促進因素

市場概況
預測期	2024-2028
2022 年市場規模	29.8億美元
2028 年市場規模	37.1億美元
2023-2028 年CAGR	3.90%
成長最快的細分市場	網路藥局
最大的市場	北美洲

研究進展

艾伯維公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
梯瓦製藥工業股份有限公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
Amneal 製藥股份有限公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
諾華公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
Zydus 生命科學有限公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
維亞特里斯公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
禮來公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
太陽藥業有限公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
雅培實驗室有限公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
盧平有限公司。
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis

第 17 章：策略建議

第 18 章：關於我們與免責聲明

簡介目錄

Product Code: 19552

Global Fibromyalgia Treatment Market has valued at USD 2.98 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 3.90% through 2028. Fibromyalgia treatment is a comprehensive approach aimed at managing the symptoms and improving the quality of life for individuals living with fibromyalgia, a chronic pain condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and often, psychological symptoms. Treatment for fibromyalgia typically involves a combination of medical, psychological, and lifestyle strategies tailored to the individual patient's needs and preferences. Physical therapists develop tailored exercise programs that focus on improving flexibility, strength, and overall physical function. Gentle, low-impact exercises are typically recommended, such as swimming, walking, or tai chi. Regular follow-up with healthcare providers is crucial to assess treatment effectiveness and make necessary adjustments to medications or other therapies. Monitoring for potential side effects and addressing them promptly is part of medication management.

The increasing prevalence of fibromyalgia worldwide, particularly in developed countries, has been a significant driver for the market. More people being diagnosed with fibromyalgia creates a larger patient pool in need of treatment. Ongoing research into the underlying causes of fibromyalgia and the development of new treatment modalities have expanded the range of available therapies and driven market growth. Pharmaceutical companies have been actively investing in the development of drugs specifically targeting fibromyalgia symptoms, including pain, sleep disturbances, and mood disorders. The trend toward multimodal approaches to fibromyalgia treatment, combining medications, physical therapy, psychological interventions, and lifestyle changes, has increased the demand for various treatment options. Government healthcare initiatives and policies aimed at improving the management of chronic pain conditions, including fibromyalgia, have bolstered the market. As the global population continues to age, the prevalence of chronic pain conditions like fibromyalgia is expected to rise, further boosting the demand for treatment. A shift toward patient-centric care, where treatment plans are tailored to individual needs and preferences, has increased the demand for a variety of treatment options.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 2.98 Billion
Market Size 2028	USD 3.71 Billion
CAGR 2023-2028	3.90%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Advancements in Research

One of the significant challenges in fibromyalgia has been the lack of objective diagnostic biomarkers. Researchers have been working to identify biomarkers in blood, cerebrospinal fluid, or other biological samples that could aid in the diagnosis and monitoring of fibromyalgia. Genetic research has provided insights into the genetic predisposition to fibromyalgia. Identifying specific genetic markers associated with the condition may lead to targeted treatments in the future. Research has emphasized the role of central sensitization, which involves an amplified response to pain signals in the central nervous system. Understanding these mechanisms has led to the development of medications targeting neurotransmitters involved in pain perception. Some studies have suggested that neuroinflammation may play a role in fibromyalgia. Investigating the involvement of inflammatory processes in the central nervous system has led to potential treatment approaches. Advancements in neuroimaging techniques, such as functional MRI (fMRI) and positron emission tomography (PET), have allowed researchers to visualize and study brain activity in individuals with fibromyalgia. These studies help in understanding how pain processing differs in fibromyalgia patients. Pharmaceutical companies have been conducting clinical trials for medications targeting fibromyalgia symptoms, including pain, sleep disturbances, and mood disorders. Some medications, such as duloxetine and pregabalin, have received regulatory approvals for fibromyalgia treatment.

Research has supported the effectiveness of non-pharmacological treatments, including cognitive-behavioral therapy (CBT), exercise therapy, and mindfulness-based interventions, in improving fibromyalgia symptoms and quality of life. There is a growing emphasis on personalized medicine in fibromyalgia treatment, where treatment plans are tailored to individual patient profiles based on factors like symptom severity, comorbid conditions, and genetic markers. Researchers are increasingly incorporating patient-reported outcomes and quality of life assessments in clinical trials to better understand treatment efficacy from the patient's perspective. The use of digital health tools and wearables has allowed for real-time monitoring of fibromyalgia symptoms and treatment responses, providing valuable data for research and patient care. Research has explored the effectiveness of complementary and alternative therapies, such as acupuncture, yoga, and dietary interventions, as adjuncts to traditional treatment approaches. Long-term observational studies are helping researchers gain insights into the natural progression of fibromyalgia, treatment outcomes over time, and factors that influence symptom fluctuations. This factor will help in the development of the Global Fibromyalgia Treatment Market.

High Prevalence of Fibromyalgia

Fibromyalgia affects a substantial number of individuals worldwide. The condition is estimated to impact millions of people, and its prevalence varies from region to region. A larger patient population naturally leads to a higher demand for treatment options. As awareness about fibromyalgia has grown among healthcare professionals and the public, more individuals are seeking medical attention and diagnosis. This increased awareness results in more people being identified as having fibromyalgia and subsequently needing treatment. High prevalence often means that more healthcare providers are diagnosing fibromyalgia. Improved diagnostic criteria and guidelines also contribute to earlier and more accurate diagnoses, driving the need for appropriate treatment. Fibromyalgia can significantly impact a person's quality of life, causing pain, fatigue, sleep disturbances, and psychological symptoms. Individuals with fibromyalgia often seek treatment to improve their overall well-being and functional ability.

The economic burden of fibromyalgia, including healthcare costs and lost productivity, is substantial. As a result, individuals with fibromyalgia and healthcare systems have a strong incentive to find effective treatments to reduce the economic impact of the condition. The high prevalence of fibromyalgia has motivated pharmaceutical companies and researchers to invest in the development of new treatments. This investment in research and innovation contributes to the availability of a variety of treatment options. Patient advocacy groups and organizations have played a crucial role in raising awareness about fibromyalgia and advocating for better treatment options. They contribute to a greater demand for effective therapies. Fibromyalgia is more common in middle-aged and older adults. As the global population continues to age, the prevalence of fibromyalgia is expected to rise, further increasing the demand for treatment. The recognition that fibromyalgia often requires a combination of treatment approaches, including medications, physical therapy, and psychological interventions, drives the demand for a comprehensive and personalized treatment plan. This factor will pace up the demand of the Global Fibromyalgia Treatment Market.

Increasing Pharmaceutical Innovations

Pharmaceutical companies are continually researching and developing new medications specifically designed to address the symptoms and underlying mechanisms of fibromyalgia. These innovative drugs aim to provide more effective and targeted treatment options for patients, increasing the demand for advanced therapies. Innovations in drug development lead to medications that are often more effective in managing the pain, sleep disturbances, and psychological symptoms associated with fibromyalgia. As the efficacy of treatments improves, more patients and healthcare providers seek these options. Pharmaceutical innovations may result in medications with fewer side effects or better tolerability profiles. Patients are more likely to adhere to treatment plans when they experience fewer adverse effects, which drives demand. When new fibromyalgia medications receive regulatory approvals, such as FDA approval in the United States or approvals from other relevant agencies worldwide, it legitimizes their use and encourages healthcare providers to prescribe them. This approval process is often based on clinical trials that demonstrate safety and efficacy. As patients become aware of new treatment options through healthcare providers, patient advocacy groups, and direct-to-consumer advertising, they may request these innovative treatments, driving demand within the market.

The presence of multiple pharmaceutical companies developing fibromyalgia treatments fosters competition. This competition can lead to a wider range of treatment choices and improved access for patients, ultimately increasing demand. Ongoing research into the underlying mechanisms of fibromyalgia and potential drug targets keeps the field dynamic. New discoveries may lead to the development of novel medications, which generate interest among healthcare providers and patients alike. Innovations may lead to more personalized and tailored treatment approaches. Tailoring treatments to individual patient need and profiles can result in better outcomes, driving demand for these specialized therapies. Innovations may also promote the use of combination therapies, where different drugs are used in tandem to address various fibromyalgia symptoms. This approach offers comprehensive symptom management and encourages the demand for multiple medications. As innovative fibromyalgia treatments become available, their distribution often expands globally. This broader availability increases the global demand for advanced fibromyalgia therapies. This factor will accelerate the demand of the Global Fibromyalgia Treatment Market.

Key Market Challenges

Variability in Symptoms

Fibromyalgia is known for its heterogeneity, with patients experiencing a wide range of symptoms and symptom severity. What works for one patient may not work for another, leading to a need for personalized treatment plans tailored to everyone's unique symptoms and needs. The variability in symptoms can complicate the diagnostic process, as fibromyalgia can mimic other conditions. Healthcare providers must carefully consider the patient's symptom profile and medical history for accurate diagnosis. The response to treatments can vary significantly among patients. What may be effective in managing pain for one person might not have the same effect on another. This variability requires ongoing monitoring and adjustment of treatment plans.

Due to the diverse symptomatology, fibromyalgia often requires a multimodal treatment approach, combining medications, physical therapy, psychological interventions, and lifestyle modifications. Coordinating these various treatment modalities can be challenging. Finding the most effective treatment for a particular patient may involve a trial-and-error process, which can be frustrating for both patients and healthcare providers. This can also lead to delayed symptom relief. While some individuals primarily experience physical symptoms, others may have a significant psychological component to their fibromyalgia. This variability necessitates a holistic approach that addresses mental health alongside physical symptoms. Variability in treatment responses can impact patient satisfaction. Patients who do not experience relief from their symptoms may become disillusioned with treatment options. Conducting clinical trials and research on fibromyalgia treatments can be complicated by the diversity of symptoms. Researchers must carefully select and stratify study participants to ensure meaningful results. Developing standardized treatment guidelines can be challenging due to the variability in symptoms. Healthcare organizations and professional societies must consider this variability when creating recommendations.

Limited Treatment Options

Fibromyalgia is a complex condition with a range of symptoms, including chronic pain, fatigue, sleep disturbances, and psychological symptoms. The limited treatment options may not fully address all these symptoms for all patients, leading to incomplete symptom management. Some patients may not tolerate or respond well to the available medications commonly prescribed for fibromyalgia, such as antidepressants and anticonvulsants. This can limit treatment choices and effectiveness. Medications used to treat fibromyalgia can have side effects, which can be a barrier to their use. Patients may discontinue treatment due to intolerable side effects, leaving them with even fewer options. A subset of fibromyalgia patients may be resistant to the available treatments, meaning that these treatments have limited effectiveness. Identifying alternative treatments for these individuals can be challenging.

Some treatments, such as opioids, are not recommended for fibromyalgia due to concerns about dependence and addiction. The limited availability of effective non-opioid pain management options can be a challenge. Non-pharmacological treatments, including physical therapy, cognitive-behavioral therapy (CBT), and exercise, are important components of fibromyalgia management. However, access to and availability of these therapies can be limited, especially in some regions. Some fibromyalgia treatments, especially when considering a multimodal approach, can be costly. This can be a barrier for patients who may not have adequate insurance coverage or financial resources. There has been a need for the development of novel therapies specifically targeting fibromyalgia. The limited number of new drugs or treatments entering the market can hinder progress in improving treatment options. Limited treatment options can lead to patient dissatisfaction and frustration, as individuals may struggle to find a treatment that effectively manages their symptoms and improves their quality of life.

Key Market Trends

Lifestyle Management

Healthcare providers are increasingly adopting a multidisciplinary approach to fibromyalgia treatment, which includes lifestyle management as a core component. This approach may involve collaboration between rheumatologists, pain specialists, physical therapists, psychologists, and other healthcare professionals. Tailoring treatment plans to the individual patient's needs and preferences is a key aspect of managing fibromyalgia. Lifestyle management strategies are chosen based on the patient's specific symptoms, challenges, and goals. Regular exercise and physical activity have been shown to improve symptoms of fibromyalgia, including pain, fatigue, and sleep disturbances. Healthcare providers are increasingly recommending exercise programs tailored to the patient's capabilities and preferences. Some individuals with fibromyalgia find that dietary changes, such as reducing the consumption of certain foods or additives, can help manage their symptoms. Nutrition counseling may be part of the treatment plan. Addressing sleep disturbances is a crucial aspect of fibromyalgia management. Lifestyle management includes adopting good sleep hygiene practices and developing a sleep routine that promotes restorative sleep. Stress can exacerbate fibromyalgia symptoms. Patients are often encouraged to practice stress-reduction techniques such as mindfulness, meditation, relaxation exercises, and stress management counseling.

Learning how to pace activities to avoid overexertion and symptom flares is a valuable lifestyle management skill for individuals with fibromyalgia. Occupational therapists may help patients develop effective pacing strategies. Cognitive-behavioral therapy (CBT) and other psychological interventions are used to address the psychological symptoms associated with fibromyalgia. Lifestyle management includes access to psychological support and coping strategies. For patients who are overweight or obese, weight management may be part of the treatment plan. Achieving and maintaining a healthy weight can help reduce the strain on joints and improve overall well-being. Healthcare providers emphasize patient education as a critical aspect of lifestyle management. Educating patients about their condition, self-care strategies, and the importance of adherence to treatment plans empowers them to take an active role in their health.

Segmental Insights

Drug class Insights

In 2022, the Global Fibromyalgia Treatment Market largest share was held by Antipileptic segment and is predicted to continue expanding over the coming years. Antidepressant medications, particularly certain types of antidepressants like tricyclic antidepressants (TCAs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs), have been found to be effective in managing the chronic pain associated with fibromyalgia. These medications can help alleviate pain symptoms and improve the quality of life for fibromyalgia patients. Fibromyalgia is often characterized by neuropathic pain, which involves abnormalities in the way the nervous system processes pain signals. Antidepressants, especially SNRIs like duloxetine, are known to modulate neurotransmitters involved in pain perception, which can be beneficial for fibromyalgia patients. Antidepressants can also have a positive impact on sleep patterns, which are frequently disrupted in individuals with fibromyalgia. Improved sleep can contribute to better overall well-being and pain management. Fibromyalgia is often associated with symptoms such as depression and anxiety. Antidepressants, as the name suggests, are designed to address these mood-related symptoms, providing dual benefits in managing both physical and emotional aspects of the condition.

Distribution Channel Insights

In 2022, the Global Fibromyalgia Treatment Market largest share was held by Hospital Pharmacies segment and is predicted to continue expanding over the coming years. Hospital pharmacies often stock a wide range of specialized medications, including those used in the treatment of chronic and complex conditions like fibromyalgia. They are equipped to provide both inpatient and outpatient services, making them a convenient source for patients with fibromyalgia. Many patients with fibromyalgia are initially diagnosed and prescribed medications in hospital settings, particularly if they are admitted for pain management, diagnosis, or related health issues. Hospital pharmacies play a key role in dispensing these initial prescriptions. Fibromyalgia treatment may involve complex medication regimens, including the use of multiple medications to manage different symptoms. Hospital pharmacies are well-equipped to manage and dispense these complex regimens. Hospitals often have specialized pain clinics and rheumatology departments where patients with fibromyalgia receive comprehensive care. Hospital pharmacies are closely aligned with these departments, ensuring timely access to necessary medications. Fibromyalgia patients may occasionally require hospitalization for severe symptoms or complications. During hospital stays, medications are dispensed through hospital pharmacies.

Regional Insights

The North America region dominates the Global Fibromyalgia Treatment Market in 2022. North America, particularly the United States, has reported a relatively high prevalence of fibromyalgia compared to other regions. This higher prevalence creates a larger patient population in need of treatment and drives demand for fibromyalgia-related healthcare services and products. North America boasts a well-developed and advanced healthcare infrastructure, with many specialized clinics, hospitals, and healthcare providers that focus on chronic pain management, including fibromyalgia treatment. The region is home to numerous pharmaceutical companies that invest in research and development of medications and therapies for fibromyalgia. These innovations are more readily available in the region. In North America, there is generally good access to healthcare services, which ensures that fibromyalgia patients can receive timely diagnoses and access to treatment options.

Key Market Players

AbbVie Inc.

Teva Pharmaceutical Industries Ltd.

Amneal Pharmaceuticals LLC

Novartis AG

Zydus Lifesciences Limited

Viatris Inc.

Eli Lilly and Company

Sun Pharmaceutical Industries Limited

Abbott Laboratories Ltd.

Lupin Limited.

Report Scope:

In this report, the Global Fibromyalgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fibromyalgia Treatment Market, By Drug class:

Antidepressants
Antipileptic
Muscle Relaxants
Others

Fibromyalgia Treatment Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Fibromyalgia Treatment Market, By region:

North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fibromyalgia Treatment Market.

Available Customizations:

Global Fibromyalgia Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fibromyalgia Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Class (Antidepressants, Antipileptic, Muscle Relaxants, Others)
- 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
5.3. Market Map

6. Asia Pacific Fibromyalgia Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Distribution Channel
- 6.2.3. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Fibromyalgia Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Class
    - 6.3.1.2.2. By Distribution Channel
- 6.3.2. India Fibromyalgia Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Class
    - 6.3.2.2.2. By Distribution Channel
- 6.3.3. Australia Fibromyalgia Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Class
    - 6.3.3.2.2. By Distribution Channel
- 6.3.4. Japan Fibromyalgia Treatment Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Drug Class
    - 6.3.4.2.2. By Distribution Channel
- 6.3.5. South Korea Fibromyalgia Treatment Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Drug Class
    - 6.3.5.2.2. By Distribution Channel

7. Europe Fibromyalgia Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Distribution Channel
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Fibromyalgia Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Class
    - 7.3.1.2.2. By Distribution Channel
- 7.3.2. Germany Fibromyalgia Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Class
    - 7.3.2.2.2. By Distribution Channel
- 7.3.3. Spain Fibromyalgia Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Distribution Channel
- 7.3.4. Italy Fibromyalgia Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Class
    - 7.3.4.2.2. By Distribution Channel
- 7.3.5. United Kingdom Fibromyalgia Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Class
    - 7.3.5.2.2. By Distribution Channel

8. North America Fibromyalgia Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Distribution Channel
- 8.2.3. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Fibromyalgia Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Class
    - 8.3.1.2.2. By Distribution Channel
- 8.3.2. Mexico Fibromyalgia Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Class
    - 8.3.2.2.2. By Distribution Channel
- 8.3.3. Canada Fibromyalgia Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Class
    - 8.3.3.2.2. By Distribution Channel

9. South America Fibromyalgia Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Distribution Channel
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Fibromyalgia Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Class
    - 9.3.1.2.2. By Distribution Channel
- 9.3.2. Argentina Fibromyalgia Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Class
    - 9.3.2.2.2. By Distribution Channel
- 9.3.3. Colombia Fibromyalgia Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Class
    - 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Fibromyalgia Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Distribution Channel
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Fibromyalgia Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Class
    - 10.3.1.2.2. By Distribution Channel
- 10.3.2. Saudi Arabia Fibromyalgia Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Class
    - 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Fibromyalgia Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Class
    - 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Fibromyalgia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. AbbVie Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
16.2. Teva Pharmaceutical Industries Ltd.
- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis
16.3. Amneal Pharmaceuticals LLC
- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis
16.4. Novartis AG
- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis
16.5. Zydus Lifesciences Limited
- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis
16.6. Viatris Inc.
- 16.6.1. Business Overview
- 16.6.2. Company Snapshot
- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
16.7. Eli Lilly and Company
- 16.7.1. Business Overview
- 16.7.2. Company Snapshot
- 16.7.3. Products & Services
- 16.7.4. Financials (In case of listed companies)
- 16.7.5. Recent Developments
- 16.7.6. SWOT Analysis
16.8. Sun Pharmaceutical Industries Limited
- 16.8.1. Business Overview
- 16.8.2. Company Snapshot
- 16.8.3. Products & Services
- 16.8.4. Financials (In case of listed companies)
- 16.8.5. Recent Developments
- 16.8.6. SWOT Analysis
16.9. Abbott Laboratories Ltd.
- 16.9.1. Business Overview
- 16.9.2. Company Snapshot
- 16.9.3. Products & Services
- 16.9.4. Financials (In case of listed companies)
- 16.9.5. Recent Developments
- 16.9.6. SWOT Analysis
16.10. Lupin Limited.
- 16.10.1. Business Overview
- 16.10.2. Company Snapshot
- 16.10.3. Products & Services
- 16.10.4. Financials (In case of listed companies)
- 16.10.5. Recent Developments
- 16.10.6. SWOT Analysis